L01XC19 blinatumomab
ATC group of level 5 – chemical substance · in plain English: cancer medicines
This site has the patient leaflet or the SPC of 2 medicines in this group.
- 2 prescription only (POM)
Active substance: Blinatumomab – all medicines with this substance, also in combinations.
Place in the ATC classification
- L Antineoplastic and immunomodulating agents 1,791 medicines
- L01 Antineoplastic agents 1,025 medicines
- L01X Other antineoplastic agents 225 medicines
- L01XC Monoclonal antibodies, antineoplastic 73 medicines
- L01XC19 blinatumomab 2 medicines
- L01XC Monoclonal antibodies, antineoplastic 73 medicines
- L01X Other antineoplastic agents 225 medicines
- L01 Antineoplastic agents 1,025 medicines
Medicines
| Medicine | Legal category |
|---|---|
| Blincyto SPC | Prescription only (POM) |
| Blincyto 38.5 micrograms powder for concentrate and solution for solution for infusion SPC | Prescription only (POM) |
Other groups of the same level
- L01XC02 rituximab 10 medicines
- L01XC03 trastuzumab 14 medicines
- L01XC05 gemtuzumab ozogamicin 1 medicine
- L01XC06 cetuximab 1 medicine
- L01XC07 bevacizumab 12 medicines
- L01XC08 panitumumab 1 medicine
- L01XC09 catumaxomab 1 medicine
- L01XC10 ofatumumab 1 medicine
- L01XC11 ipilimumab 1 medicine
- L01XC12 brentuximab vedotin 1 medicine
- L01XC13 pertuzumab 1 medicine
- L01XC14 trastuzumab emtansine 2 medicines
- L01XC15 obinutuzumab 1 medicine
- L01XC16 dinutuximab beta 1 medicine
- L01XC17 nivolumab 2 medicines
- L01XC21 ramucirumab 1 medicine
- L01XC24 daratumumab 2 medicines
- L01XC25 mogamulizumab 1 medicine
- L01XC26 inotuzumab ozogamicin 1 medicine
- L01XC27 olaratumab 1 medicine
- L01XC28 durvalumab 1 medicine
- L01XC31 avelumab 1 medicine
- L01XC32 atezolizumab 1 medicine
- L01XC33 cemiplimab 1 medicine
- L01XC35 tafasitamab 1 medicine
- L01XC38 isatuximab 1 medicine
- L01XC39 belantamab mafodotin 2 medicines
- L01XC40 dostarlimab 1 medicine
Other names of the ATC group
- German: L01XC19 Blinatumomab
- Spanish: L01XC19 BLINATUMOMAB
- German: L01XC19 Blinatumomab
- Polish: L01XC19 BLINATUMOMAB
- Turkish: L01XC19 blinatumomab
Sources
- Patient leaflets and SPCs: the MHRA product information (products.mhra.gov.uk) and the European Medicines Agency (EMA)
- Active substances, ATC codes and legal categories: the NHS Dictionary of Medicines and Devices (dm+d), NHS Business Services Authority
- World Health Organization (WHO): ATC/DDD classification, group L01XC19
Contains public sector information licensed under the Open Government Licence v3.0.
Ask your doctor or pharmacist which medicine is right for you.